Advertisements


Trillium Therapeutics doses first patient with TTI-622

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 14th, 2018

Cara Therapeutics doses first patient in Phase 2 trial of Korsuva for pruritus

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 19th, 2018

Aclaris Therapeutics doses first patient in Phase 2 clinical trial of ATI-501

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 26th, 2018

Aclaris Therapeutics doses first patient in ATI-502 pilot study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: dealsSource: nytApr 23rd, 2018

Spark Therapeutics stock plummets 28% premarket on hemophilia trial"s patient safety concerns

Spark Ther.....»»

Category: topSource: marketwatchAug 7th, 2018

Spark Therapeutics stock plummets 25% premarket on hemophilia trial"s patient safety concerns

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchAug 7th, 2018

Cara doses first patient in second pivotal Phase 3 efficacy trial of KORSUVA

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 7th, 2018

Halozyme: Genentech doses first patient in Phase 3 study of Perjeta, Herceptin

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 26th, 2018

Sangamo Announces TxCell Acquisition, Patient Dosing In SB-318

Sangamo Therapeutics Inc (NASDAQ: SGMO) announced Monday it would acquire TxCell for about €72 million to complement its ex vivo gene editing program. read more.....»»

Category: blogSource: benzingaJul 23rd, 2018

Mersana Therapeutics shares plummet 40% after patient death in cancer trial

Mersana Therapeutics Inc. said early Thursday that, after the company reported a patient death in its cancer drug trial, the Food and Drug Administrat.....»»

Category: topSource: marketwatchJul 19th, 2018

Mersana Therapeutics" cancer trial placed on partial clinical hold by FDA after patient death

Mersana Therapeutics Inc. said early Thursday that, after the company reported a patient de.....»»

Category: topSource: marketwatchJul 19th, 2018

Company Spotlight: Trillium Therapeutics

Company Spotlight: Trillium Therapeutics.....»»

Category: topSource: seekingalphaJul 18th, 2018

Xencor doses first patient in Phase 1 study of solid tumors candidate

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 12th, 2018

Aldeyra doses last patient in dry eye disease Phase 2b clinical trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 12th, 2018

Codexis doses first patient in CDX-6114 Phase 1a trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 9th, 2018

Quark Pharmaceuticals doses first patient in Phase 3 clinical trial of QPI-1002

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 9th, 2018

Zai Lab doses first patient in Phase 3 China registration trial of ZL-2306

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 29th, 2018

MyoKardia doses first patient in Phase 3 EXPLORER-HCM trial of mavacamten

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 26th, 2018

Actinium Pharmaceuticals doses 38th patient in Iomab-B pivotal SIERRA trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 26th, 2018

Revance doses first patient in Phase 3 RT002 program for CD treatment

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 21st, 2018

Heron Therapeutics stock rockets 30% on high hopes for post-surgery pain treatment

Heron Therapeutics Inc. shares surged 33.6% Thursday, after the company announced positive developments for its treatments for postoperative pain that aim to reduce patient dependence on opioids. A competitor’s stock slumped......»»

Category: topSource: marketwatchJun 21st, 2018